Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rani Therapeutics Holdings

1.21
-0.0900-6.92%
Post-market: 1.210.00000.00%16:05 EDT
Volume:184.80K
Turnover:225.77K
Market Cap:40.31M
PE:-1.15
High:1.27
Open:1.25
Low:1.17
Close:1.30
Loading ...

Company Profile

Company Name:
Rani Therapeutics Holdings
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
140
Office Location:
2051 Ringwood Avenue,San Jose,California,United States
Zip Code:
95131
Fax:
- -
Introduction:
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Directors

Name
Position
Mir Imran
Executive Chairman
Talat Imran
Chief Executive Officer and Director
Andrew Farquharson
Director
Dennis Ausiello
Director
Jean Luc Butel
Director
Laureen DeBuono
Director
Maulik Nanavaty
Director

Shareholders

Name
Position
Talat Imran
Chief Executive Officer and Director
Svai Sanford
Chief Financial Officer
Mir Hashim
Chief Scientific Officer
Mir Imran
Executive Chairman